ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX) today announced that four-year patient follow-up data from the Company's Powerlink(R) System pivotal clinical trial support the durability of the Powerlink as an endoluminal stent graft (ELG) for the treatment of abdominal aortic aneurysms (AAA). Rodney A. White, M.D., Professor of Surgery at UCLA School of Medicine and Chief of Vascular Surgery at Harbor-UCLA Medical Center, presented the data at the VEITH symposium(TM) in New York on Saturday, November 19. Dr. White's presentation, "Factors Contributing to True and Apparent Graft Migration After EVAR with the Powerlink Endograft: The Importance of AAA Sac Remodeling," included data from the 192 test patients treated with the minimally invasive Powerlink System in the pivotal trial with a mean follow-up time of 30.20 months and a maximum follow-up time of 48.62 months. Of the 192 test patients, Dr. White reported that only 24 to date have required secondary procedures. The majority of these patients were treated for Type II endoleak, indicating that the need for secondary procedure was not device specific. Additionally, Dr. White announced highlights from 53 patients followed for 48 months that included: -- 97.9% were free from AAA mortality -- There were no reported graft material failures -- There were no reported stent fractures -- Aneurysm remodeling continues, as noted by a continued reduction in both aortic sac diameter and volume "We were exceptionally pleased with the positive four-year data presented at the VEITH symposium, which is an important conference in reaching thought leaders in the endovascular community," said Endologix President and CEO Paul McCormick. "We believe this data that provides evidence of our device's durability over time will further support commercialization of the Powerlink System." About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. In October 2004, Endologix received approval to market the Powerlink in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.